

## Pharmacy & Therapeutics Committee (P&T) Meeting

### Colorado Department of Health Care Policy & Financing (HCPF)

<b>Date, Time</b>	Tuesday, October 7, 2025	1:00-5:00 PM MST
<b>Location</b>	<b>Virtual:</b> Webinar link will be available on October 6th	

### Agenda

#### 1. Call to Order and Welcome

- Quorum Confirmation
- Introductions

#### 2. Old Business

- Approval of meeting minutes from July 8, 2025, P&T meeting
- Updates from July 8, 2025, P&T Meeting

#### 3. New Business

- Updates from the Prior Authorization Call Center
- Announcement of term expirations and open positions for January 2026

---

#### 4. Review Process

- Full Review:
    - Oral presentation by manufacturers, providers, and public
    - Overview for each Drug Class, including market share overview.
    - Committee Discussion and Recommendations for each Drug Class
  - Mass Review:
    - Overview for each Drug Class, including market share overview.
- 

#### 5. Drug Class Reviews

##### A Full Review:

- Epinephrine Products
- Hepatitis C Virus Treatments
- Human Immunodeficiency Virus (HIV) Treatments
- Immune Globulins
- Newer Hereditary Angioedema (HAE) Products
- Respiratory Agents:
  - a Inhaled Beta2 Agonists (Short- and Long-Acting)
  - b Inhaled Anticholinergics and Combinations
  - c Inhaled Corticosteroids and Combinations
- Targeted Immune Modulators

##### B Mass Review:

- Antibiotics – Inhaled
- Antiherpetic Agents – Oral and Topical
- Antihistamine/Decongestant Combinations

Our mission is to improve health care access and outcomes for the people we serve while demonstrating sound stewardship of financial resources.  
www.colorado.gov/hcpf



## Agenda

- Fluoroquinolones – Oral
- Intranasal Rhinitis Agents
- Leukotriene Modifiers
- Methotrexate Products
- Newer Generation Antihistamines
- Phosphodiesterase Inhibitors

---

### 6. Presentation Requests & Stakeholder Comment Guidelines (Including Manufacturers)

- Each request must include a one-page clinical summary focused solely on clinical information (no cost, anecdotal, or economic data) and relevant only to products under PDL review.
- Presentations are limited to verbal comments with no visual aids except designated handouts.
- Approved presentations and written comments will be provided to the Committee in advance of the meeting.
- Submit requests no later than **October 2, 2025, at 5:00 PM MST** to:  
**Mohamed Duklef**, Clinical Program Manager-[mohamed.duklef@medimpact.com](mailto:mohamed.duklef@medimpact.com)  
**CC: Greg Miller**, PDL & Clinical Strategy Pharmacist – [greg.l.miller@state.co.us](mailto:greg.l.miller@state.co.us)
- For full stakeholder comment policies, visit the [P&T Committee Policies & Procedure](#) page.

---

### 7. Adjourn

- Upcoming Meeting Date: **January 6<sup>th</sup>, 2026**

### Accessibility

Reasonable accommodations will be provided upon request. Auxiliary aids and services for individuals with disabilities and language services for individuals whose first language is not English may be provided upon request. Please notify the 504/ADA Coordinator at [hcpf504ada@state.co.us](mailto:hcpf504ada@state.co.us) at least one week prior to the meeting to make arrangements.